CLINICAL TRIALS

Cervical Cancer Clinical Trials in Tennessee

10+ recruiting Cervical Cancer trials in Tennessee, simplified into plain English.

Informational only. Not medical advice. Always consult a qualified healthcare professional.
Data sourced from ClinicalTrials.gov (NLM/NIH).

RECRUITING

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced

NCT07124000 · Nashville
ACTIVE NOT RECRUITINGPhase 2

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors. The study

NCT03228667 · Knoxville
RECRUITINGNA

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

NCT05108298 · Bristol
ACTIVE NOT RECRUITINGPhase 2

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

This phase II trial studies the side effects and how well nivolumab works in treating patients with cervical cancer that has grown, come back, or spread to other places in the body. Monoclonal antibodies, such as nivolum

NCT02257528 · Chattanooga
ACTIVE NOT RECRUITINGPhase 1

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660, determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing regimen, and to obtain prelimina

NCT02503423 · Nashville
RECRUITINGPhase 2

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\],

NCT06172478 · Nashville
ACTIVE NOT RECRUITINGPhase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it fir

NCT02465060 · Chattanooga
RECRUITING

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) prog

NCT03452774 · Memphis
ACTIVE NOT RECRUITINGPhase 3

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

This randomized phase III trial studies radiation therapy and cisplatin with triapine to see how well they work compared to the standard radiation therapy and cisplatin alone in treating patients with newly diagnosed sta

NCT02466971 · Chattanooga
ACTIVE NOT RECRUITINGPhase 3

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

This study will have two phases: a sacituzumab tirumotecan safety run-in and a Phase 3 portion. The safety run-in phase will be used to evaluate the efficacy and safety of sacituzumab tirumotecan at the dose for evaluati

NCT06459180 · Germantown

RECOMMENDED RESOURCES FOR CERVICAL CANCER

🧬

Color Health

CLIA Certified

Hereditary cancer genetic testing from $99. Understand your inherited risk for breast, ovarian, colon, and other cancers — with genetic counseling included.

Get Tested →

Clinicals AI may earn a referral fee. At no cost to you.

COMMON QUESTIONS

Are there Cervical Cancer clinical trials in Tennessee?

Yes. Clinicals AI lists 10+ recruiting Cervical Cancer trials in Tennessee sourced from ClinicalTrials.gov. Browse them above or search across all states.

How do I qualify for a Cervical Cancer trial in Tennessee?

Eligibility varies by study. Most trials require a confirmed Cervical Cancer diagnosis, fall within a specific age range, and may have restrictions based on prior treatments. Review each listing's criteria and submit a contact request for more details.

Are Cervical Cancer clinical trials free to join?

Most trials cover the investigational treatment and all study-related visits. Some also offer compensation for travel and time. Always confirm the cost structure with the trial coordinator before enrolling.